Trump administration backs nuclear fusion — as a company tied to Trump invests in it
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
10 ‘better values' in the stock market, selected for the next two years